Embryonic stem cells (ESCs)
===========================

ESCs derived from the blastocyst are capable of self renewal and can remain in an undifferentiated state for indefinite passages in vitro and also can be coaxed to differentiate to different lineages ([@b62-sccaa-1-11]). This makes them the favorable candidate for developing cellular therapies against many degenerative diseases such as those outlined in [Table 1](#t1-sccaa-1-11){ref-type="table"}. Following the first successful derivation of 5 hESC lines by Thomson's group in 1998 ([@b96-sccaa-1-11]), more new hESC lines have been created ([@b37-sccaa-1-11]; [@b114-sccaa-1-11]; [@b22-sccaa-1-11]; [@b89-sccaa-1-11]). To date it is estimated, that more than 414 new hESC lines have been produced worldwide and out of which ∼78 are listed on the National Institute Health (NIH) Registry ([@b36-sccaa-1-11]). Only ∼179 of these lines are characterized to some extent and available for research. Many of these hESC lines are not clonal and are derived under different culture conditions and propagated on different feeder layers (MEF, STO, fetal muscle, skin and foreskin, adult fallopian tube epithelial cells and also some feeder free/serum free systems), hence comparison of these lines are very difficult ([@b1-sccaa-1-11]; [@b22-sccaa-1-11]; [@b2-sccaa-1-11]).

Epigenetic modifications play a significant role in maintaining pluripotency in ESCs and at the same time, very relevant in determining the somatic status of terminally differentiated cells. Accordingly, epigenetic profiles of pluripotent genes such as *Nanog* and *OCT4*, in ESCs are maintained.

The study of epigenetics -- a cell's epigenome
==============================================

Gene and protein expression profiling has long been the benchmark in characterizing cell specialization during development. However, recent emphasis is shifted in favor of epigenetic profiling (also referred to as the 'epigenome') than genomic profiling as the former is considered to play a significant role in lineage specifications. The study of epigenetics involves covalent modifications to the architectural structure of both chromatin and DNA, but not to the sequence itself. However, there are other players which regulate gene expression such as binding of DNA proteins. These modifications are heritable ([@b25-sccaa-1-11]) and often regulate gene expression to a certain extent ([@b56-sccaa-1-11]).

In contrast to gene expression profiles observed in somatic and/or differentiated cells, the ESCs have the potential of activating all gene expression profiles of all cell types from one genome. During mammalian development, almost all cells differentiate without changes to the DNA sequence, however their phenotypes are associated with certain activation (or inactivation) of genes. The differential activation/deactivation of genes depends on the presence and arrangement of functional moieties such as methyl (--CH~3~) and acetyl (--COCH~3~) groups, which forms the basis of an 'epigenetic' environment around the genomic DNA.

Understanding these complex structures of epigenetic modifications can lead to better understandings of how and when genes are activated or repressed. These patterns are established in early embryonic development and are subject to change throughout development ([@b56-sccaa-1-11]; [@b81-sccaa-1-11]).

The mechanism of DNA methylation
================================

Protein expressions determine cell phenotypes that are translated from mRNA transcripts of genomic DNA. Despite gene expression being influenced by changes in DNA sequence (single nucleotide polymorphisms -- SNPs, within protein encoding sequences), epigenetic modifications such as DNA methylation can also affect gene expression ([@b40-sccaa-1-11]).

DNA methylation forms an important means of epigenetic modifications and was first detected nearly 60 years ago, using chromatography techniques ([@b45-sccaa-1-11]). Over the past decade, transcriptional silencing of tumor suppressor genes through abnormal DNA methylation patterns has been established ([@b48-sccaa-1-11]). DNA methylation is also involved in other cellular processes such as, genomic stability ([@b78-sccaa-1-11]), X chromosome inactivation ([@b70-sccaa-1-11]), genomic imprinting ([@b25-sccaa-1-11]), chromatin structure ([@b50-sccaa-1-11]) and mammalian development ([@b81-sccaa-1-11]).

In mammalian genomes, DNA methylation occurs exclusively at the 5′ position on a cytosine nucleotide in the context of CG sequences ([@b9-sccaa-1-11]). CpG islands are regions of DNA where CG nucleotides are present at significantly higher levels than the rest of the genome, these islands often reside at 5′ ends of all housekeeping and many tissue-specific genes -- the promoter region ([@b33-sccaa-1-11]). This methylated 5′ cytosine can act as a 5th DNA base, as different cytosine methylation status affects gene transcription.

Methylated DNA is often correlated to gene repression ([@b31-sccaa-1-11]), its precise mechanism remains to be elucidated. One such explanation is that transcriptional binding sites become occupied by a group of methyl-CpG binding proteins (MeCP1, MeCP2, MBD1, MBD2) that specifically bind to methylated DNA. This explanation is supported via the findings that the binding of MeCP2, recruits histone deacetylases to repress transcription ([@b50-sccaa-1-11]; [@b73-sccaa-1-11]; [@b98-sccaa-1-11]; [@b32-sccaa-1-11]). This is also evident that these 2 epigenetic modifications; DNA methylation and histone deacetylations are inter-related. MBD2 is also known to bind with NuRD, forming a complex; MeCP1 which has gene repressive capabilities ([@b27-sccaa-1-11]).

DNA methyl transferases (DNMT) are enzymes that add methyl groups to DNA. In mammals there are 3 common transferases, DNMT1, DNMT3a, DNMT3b. DNMT1 is a methylation maintenance enzyme and targets newly synthesized DNA via its N-terminal regulatory domain which aims for the replicating foci ([@b55-sccaa-1-11]). Somatic cells are believed to preserve their methylation patterns via this manner. DNMT3a/3b are de novo methylation enzymes and are most active during 2 stages of embryonic development following the 2 rounds of global genomic demethylation ([@b72-sccaa-1-11]).

Methylation patterns are dynamic, as commonly demonstrated in reprogramming studies and they also change as cells develop physiologically ([@b28-sccaa-1-11]; [@b92-sccaa-1-11]). Demethylation occurs spontaneously as previously demonstrated ([@b14-sccaa-1-11]). Ectopically methylated genes transfected into somatic cells showed demethylating activity. Another study also showed demethylase activity via a mammalian protein which has DNA encoding for a methyl-CpG binding domain is also shown ([@b7-sccaa-1-11]). However demethylation alone is not sufficient to remove the repressive trait of methylation. This encourages scientists to look at epigenetic modifications as a whole, instead of one entity, specifically at histone modifications, as will be discussed later. Mechanisms that prevent de novo CpG methylation are unclear. Several proposed hypotheses include; DNMT3a/3b requires additional CpG binding proteins (CGBP) or other protein interaction. There may also be a constant demethylase activity, as demonstrated in the above mentioned study ([@b14-sccaa-1-11]).

All types of cells would have their own epigenomic signature. This is best depicted using DNA microarrays (for example Illumina's bead arrays), where an epigenome is expressed in a cluster analysis methylation chart, displaying cell type and CpG methylation levels. A recent study, mapped the methylation status of 23 genes (25 CpG sites) over a range of cell types ([@b8-sccaa-1-11]) ([Figure 1](#f1-sccaa-1-11){ref-type="fig"}). From this figure, it is very clear that different cell types are epigenetically (and transcriptionally) divergent from each other, otherwise referred to as being 'epigenetically unique.'

There are many techniques used to study DNA methylation patterns, but the most specific and commonly used, being bisulfite DNA sequencing ([@b30-sccaa-1-11]). Bisulfite deals structural changes to unmethylated cytosines, while methylated cytosines remain intact. With this change, one can measure the amount of DNA methylation using conventional DNA sequencing procedures ([Figure 2](#f2-sccaa-1-11){ref-type="fig"}). This is a quantitative measure and is generally correlated to gene expression profiles. A most recent study, mapped the entire genome of *Arabidopsis thaliana* using a shotgun bisulfite approach using a Next-generation sequencer, which provided a map at single base pair resolution of methylated cytosines ([@b21-sccaa-1-11]).

5′aza-2-deoxycytidine (5azadC) is a global DNA demethylation reagent that clips off methyl groups bound on 5′methyl-cytosines. 5azadC is a deoxy- form of 5-azacytidine and is more readily incorporated into DNA. This causes a more efficient inhibition of methylation than the latter ([@b71-sccaa-1-11]). Its activity is characterized by the covalent trapping of DNMT which depletes the cell of its enzymatic activity ([@b51-sccaa-1-11]). 5azadC is commonly used as a DNA methylation inhibitor and its activity has been correlated with gene expression ([@b49-sccaa-1-11]; [@b95-sccaa-1-11]; [@b51-sccaa-1-11]; [@b35-sccaa-1-11]), cellular differentiation ([@b79-sccaa-1-11]; [@b17-sccaa-1-11]) and specifically in enhancing hESC differentiation ([@b106-sccaa-1-11]).

Maintaining methylation but not de novo methylation is required for in vitro differentiation, as demonstrated previously ([@b46-sccaa-1-11]). Briefly, hypomethylated cell lines with *Dnmt3a/3b* gene knockouts restored their methylation after stable integration of DNMT1 cDNA transgene.

Although DNA methylation has been intensively studied, many questions remain to be answered, including what mechanisms prevent the de novo methylation of normal somatic cells? And the proteomic network of DNMT remains to be elucidated.

Chromatin remodeling and histone modifications
==============================================

The fundamental unit of chromatin is a nucleosome, which consists of a core of 8 histones; H2A, H2B, H3 and H4 (2 of each). Each core is surrounded by ∼147bp of DNA and is tightly wound around 1.75 turns ([Figure 3](#f3-sccaa-1-11){ref-type="fig"}). There is increasing evidence that transcriptional factors recognize signals given off by histone tail modifications. As there is an association between DNA and histones, it is not surprising that histone tail modifications (acetylation methylation, ubiquitylation and phosphorylation) also affect gene transcription.

At the molecular level, the revealing (or hiding) of binding sites that influence gene transcription are outcomes of histone tail modifications. This hiding and revealing of binding sites is determined by overall chromatin structure whether it is relaxed or compact. Acetylation of histone tails removes the positive charge, thus decreasing the affinity between the DNA and histones. This results in a structure called euchromatin and allows easier access of transcriptional factors. In contrast, the result of deacetylation, caused by histone deacetylases (HDACs) is heterochromatin, which results in tightly compacted chromatin and conceals transcriptional DNA binding sites.

Histone tails of H3 holds several amino acids that are notably studied for their correlation with gene expression; these are lysine, arginine, serine and threonine residues. Transcriptionally active genes generally harbors histone H3 lysine 9 acetylation (H3K9ac), H3K4 di-methylation (H3K4me^2^), tri-methylation (H3K4me^3^), H3K36me^3^ and H3K79me^3^. Transcriptionally repressed genes tend to harbor H3K9me^2^, H3K9me^3^, H3K27me^3^ and histones H4 lysine 20 tri-methylation (H4K20me^3^) ([@b23-sccaa-1-11]; [@b28-sccaa-1-11]; [@b60-sccaa-1-11]). Cell populations expressing high levels of gene(s) are generally enriched with euchromatic markers in their promoter regions as demonstrated in pluripotent genes *OCT4, NANOG* and heterochromatic markers of somatic gene *PAX6* of pluripotent undifferentiated carcinoma cells ([@b23-sccaa-1-11]). A recent study mapped the histone methylation marks in mouse- ESCs, neural progenitor cells and embryonic fibroblasts and highlighted the impact of H3K4me^3^ and H3K27me^3^, on transcriptionally active and inactive genes respectively ([@b66-sccaa-1-11]). Gene promoters which contained both the euchromatic and heterochromatic markers above determine switching cell developmental fates ([@b5-sccaa-1-11]).

Chromatin immunoprecipitation (ChIP) is a technique used to study chromatin remodeling including histone de/acetylation and de/methylation. Protein-DNA interaction is the basis of this technique and has been used for the past 20 years. Conventional ChIP analysis requires large numbers of starting material; cells and hence, a simplified recipe, Q^2^ChIP Assay was invented ([@b23-sccaa-1-11]). Briefly, cells are cross linked using sodium butyrate prior to lysis and sonication. Cell lysate is immunoprecipitated and reversed cross linked; unbinding of DNA-histone complexes, DNA is then isolated and used for polymerase chain reaction (PCR) assays ([Figure 4](#f4-sccaa-1-11){ref-type="fig"}).

Recruitment of histone acetyl transferases (HATs) or presence of histone deactylases (HDAC) inhibitor(s) results in histone acetylation ([@b14-sccaa-1-11]). Hyper-acetylated promoter regions correspond to gene activity ([@b40-sccaa-1-11]). Trichostatin A (TSA) is a commonly used deacetylase inhibitor, and allows re-expression of genes regulated by histone acetylations ([@b13-sccaa-1-11]), methylation ([@b77-sccaa-1-11]) and also inducing cellular differentiation ([@b44-sccaa-1-11]). Other studies have determined common enzymes that demethylate specific lysine residues which generally lead to gene activation/repression (depending on the traits of specific lysine residues): Lysine specific demethylase (LSD1) specifically demethylates H3K4 ([@b88-sccaa-1-11]), Ubiquitously transcribed tetratricopeptide repeat, X chromosome (UTX) and Jumonji domain containing 3 (JMJD3) specifically demethylates H3K27 ([@b43-sccaa-1-11]).

The increase of histone acetylation is associated with a decrease in global methylation ([@b46-sccaa-1-11]; [@b77-sccaa-1-11]) and a gene's methylated state is determined by the balance between demethylase activity and state of histone acetylation ([@b14-sccaa-1-11]). Treatment of cells with TSA showed re-expression of some methylation-silenced tumor suppressor genes indicating that methylation is the dominant epigenetic suppressor of densely methylated genes ([@b13-sccaa-1-11]). Another study displays similar results while providing evidence that TSA inhibits DNMT1 ([@b47-sccaa-1-11]), which plays the role of 5azadC (as mentioned earlier); demethylation of tumor suppressor genes ([@b65-sccaa-1-11]).

Lineage specifications
======================

Recently, the study of epigenetic changes during differentiation of ESCs and de-differentiation of somatic cells has revealed some interesting results. More differentiated cells generally harbor more epigenetic modifications as demonstrated in mouse fibroblast cells (fully differentiated cells), where a combination of Trichostatin A (TSA) and 5′aza-2-deoxycytidine (5azadC), was required for *OCT4* re-expression, whereas in trophoblast stem cells (less differentiated cells), either 5′azadC or TSA alone can re-activate *OCT4* expression ([@b40-sccaa-1-11]). However, certain cells do retain their ability to switch cell developmental fates through balancing of euchromatic and heterochromatic markers ([@b66-sccaa-1-11]). One exception to the above rule, applies to germ line cells (non-somatic cells), namely -- primordial germ cells (PGCs). PGCs undergoes dynamic methylation changes ([@b97-sccaa-1-11]) which forms the basis of regulating germ cell-specific gene expression ([@b59-sccaa-1-11]). Derivatives of PGCs, such as; arrested metaphase II eggs and mature sperm exhibit hypomethylated major and minor satellite sequences whereas in comparison to somatic cells, are hypermethylated ([@b107-sccaa-1-11]). This is one of the best examples using epigenetic modifications in lineage specification. Somatic cells maintain their gene expressions after mitosis through epigenetic mechanisms, a process often referred to as 'cellular memory.' However, the cellular memory present in PGCs remains in a 'reprogrammable' state with the potential event of totipotency.

Another example of epigenetic lineage specification include specific CpG methylation of promoter regions as previously demonstrated ([@b94-sccaa-1-11]). Briefly, a certain CG found in the STAT3 binding element within the *GFAP* promoter region of neuroepitheilial cells/post-mitotic neurons is highly methylated and is a sign of *GFAP* suppression. As these cells differentiate into astrocytes, this level of methylation is decreased resulting in the expression of *GFAP* ([@b94-sccaa-1-11]). Therefore methylation of the STAT3 recognition sequence results in *GFAP* suppression.

Epigenetic modifications of stem cells
======================================

Cellular differentiation
------------------------

There are 3 major stages of epigenetic modifications during gametogenesis and embryonic development. The first occurs in primordial germ cells, where the imprints of genes are erased, shown by the lack of methylation ([@b86-sccaa-1-11]; [@b59-sccaa-1-11]). The second stage involves epigenetic acquisition in maturing gametes, namely oocytes ([@b58-sccaa-1-11]) and spermatozoan ([@b74-sccaa-1-11]). The third stage occurs during fertilization and usually involves maintenance of methylation in imprinted genes, while other genes gradually lose their methylation ([@b63-sccaa-1-11]; [@b75-sccaa-1-11]).

As described above, epigenetic modifications are dynamic throughout cellular differentiation. Many recent studies on directed differentiation of ESCs used epigenetic modifying agents 5azadC and TSA to enhance the efficiency of differentiation. Differentiation of ESCs to cardiomyocytes was enhanced with 5azadC and TSA ([@b106-sccaa-1-11]; [@b44-sccaa-1-11]). A recent report attempts to describe the dynamics of DNA methylation of differentially methylated regions (DMRs) in 5azadC-induced adipocyte differentiation ([@b85-sccaa-1-11]). Although a majority of associated genes exhibited no change in methylation profiles, a series of 8 out of 65 tissue-dependent DMRs underwent either methylation, demethylation or were transient, from stem cell to mature adipocytes.

In a recent study it is demonstrated that although TSA does not improve astrocyte differentiation, it assisted in the derivation of neurons with normal electrophysiological membrane properties and elongation of dendrites ([@b3-sccaa-1-11]).

Cellular reprogramming and dedifferentiation
--------------------------------------------

Somatic cell nuclear transfer (SCNT) is a process whereby the derivation of cloned animals ([@b104-sccaa-1-11]) and donor-matched cell lines ([@b99-sccaa-1-11]) is made possible. SCNT is an emerging area in stem cell research and involves transferring nuclei of somatic cells into enucleated oocytes with the aim to derive embryonic stem cells with the same genetic makeup as the 'donor' somatic cell. From a clinical perspective, such cells, when transplanted, should not be rejected due to incompatible immune response.

SCNT is also useful for studying drug toxicologies in embryonic cell lines derived from a somatic cell's genome carrying a certain disease(s) such as those listed in [Table 1](#t1-sccaa-1-11){ref-type="table"}. This technique has also been used to generate live cloned offspring in various animal species but not in humans ([@b20-sccaa-1-11]; [@b64-sccaa-1-11]; [@b83-sccaa-1-11]). However, it remains as an inefficient technique. Many factors influencing SCNT efficiency include; donor cell phenotype ([Table 2](#t2-sccaa-1-11){ref-type="table"}), developmental stage of recipient oocytes during nuclear transfer ([@b38-sccaa-1-11]), cell cycle stage of donor somatic cell ([@b52-sccaa-1-11]), type of zygote/embryo activation method ([@b18-sccaa-1-11]) and recently, epigenetic modifications including DNA methylation and histone acetylation ([@b53-sccaa-1-11]).

Epigenetic studies play a significant role in determining reprogramming during SCNT ([@b12-sccaa-1-11]) and also in a recently developed technology; induced pluripotent stem (iPS) cells, that is, reprogramming somatic cells to pluripotent state by transducing specific pluripotency-associated genes into the somatic cells ([@b93-sccaa-1-11]; [@b92-sccaa-1-11]; [@b103-sccaa-1-11]; [@b113-sccaa-1-11]). These studies have analysed DNA methylation and histone modifications to confirm their reprogrammed somatic cells have reverted back into a pluripotent state (and even to totipotent status in mice). These epigenetic analyses along with gene expression patterns are essential to specify and confirm the identity of the pluripotent lineage.

As indicated in [Table 2](#t2-sccaa-1-11){ref-type="table"}, SCNT remains as an inefficient process and many studies are being carried out to improve SCNT efficiency. In a recent study led by Jaenisch ([@b10-sccaa-1-11]), it has been demonstrated that less differentiated somatic cells increases SCNT efficiency. It has been shown, by using cells which carry a hypomorphic allele of *Dnmt1* (which results in 'global demethylation' of the donor genome), higher efficiency could be achieved (65%). This paper may well provide a spark in the future for efficient establishment of nuclear transfer-ESC lines. However higher efficiency of cloning was also achieved by using differentiated cells (namely, granulocytes) compared to that with less differentiated hematopoietic stem cells ([@b91-sccaa-1-11]). Conclusions from both these studies, although correct, encourage us to look at the epigenetic nature of donor cells and how certain somatic epigenomes influences SCNT efficiency.

Bisulfite sequencing and Q^2^ChIP analyses are useful for studying a limited number of genes at one time. However, it is more convenient to use immunocytochemistry to visually observe global epigenetic patterns and/or dynamics within cell populations. Antibodies specific to epigenetic markers (for eg, 5′methyl-cytosines and H3K9 methylation) is an invaluable tool to study the epigenetic dynamics by observing intensities of fluorescence ([@b4-sccaa-1-11]; [@b110-sccaa-1-11]; [@b86-sccaa-1-11]).

SCNT embryos in animals tend to exhibit aberrant epigenetic makers as compared to those produced with traditional IVF technology These embryos tend to exhibit abnormally higher methylation levels during pre-implantation embryogenesis ([@b24-sccaa-1-11]; [@b4-sccaa-1-11]). H3K9 acetylation levels in SCNT embryos, on the other hand, were at a lower level than IVF embryos and suggest active histone deacetylase activity. Inhibition of histone deacetylases (HDACs) via trichostatin A, may bring up the levels of acetylation consistent with IVF embryos. These strategies have previously been demonstrated in mice ([@b26-sccaa-1-11]; [@b53-sccaa-1-11]) and should be adapted in future studies, for efficient reprogramming of donor nuclei, which is believed to be the major cause for SCNT low efficiency.

Conclusions
===========

Epigenetics is an exponentially growing field in ESC research, especially in cellular reprogramming studies. The aim to establish patient-matched ESC lines is currently hindered by the fact that there are aberrant epigenetic modifications during the reprogramming process and needs to be addressed. Epigenetic modifications are dynamic and directed differentiation studies should aim to address these issues, since growth factors and supplements is not sufficient for the directed differentiation of ESCs. Both DNA methylation and histone modifications are inseparable entities when it comes to cellular differentiation and de-differentiation. Epigenetic changes induced by using specific reagents have the prospects of studying both the cellular differentiation and de-differentiation processes as demonstrated in some previous studies.
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![Methylation analysis chart. Each column represents a different cell type, while each row is a different genes/CpG site. Each cytosine is graded from being heavily methylated (1) to largely unmethylated (0).](sccaa-1-11f1){#f1-sccaa-1-11}

![Process of bisulfite DNA sequencing. Genomic DNA is treated with sodium bisulfite which deals structural and irreversible changes to a cytosine through denaturation, deamination and desulphonation processes. Taking advantage of these changes, the DNA is PCR-amplified and ligated to plasmid vectors for transformation into *Escherichia coli*. White colonies are hand picked and plasmid DNA extracted for automated DNA sequencing. Closed circles represent methylated CpGs and open represent unmethylated CpGs.](sccaa-1-11f2){#f2-sccaa-1-11}

![A diagrammatic representation of one chromatin unit. A nucleosome, consisting of 4 histones types; H2A, H2B, H3 and H4 with DNA (blue) tightly wound around the core unit. Histone tails (yellow) protrude from the centre of the histones through the DNA strands (blue).](sccaa-1-11f3){#f3-sccaa-1-11}

![Quick and Quantitative Chromatin Immuno-precipitation (Q^2^ChIP). Cells were harvested and treated with sodium butyrate to allow DNA-protein crosslinking. Cells were lysed and sonicated to produce fragments (∼500 bp). Chromatin fragments were allowed to conjugate to 'antibody-paramagnetic bead complexes' (specific for H3K9ac). The solution is magnetically separated and purified fragments are reversed crosslinked and subjected to proteinase K digestion. Isolated DNA is now ready for downstream PCR processes.](sccaa-1-11f4){#f4-sccaa-1-11}

###### 

A concise list of some degenerative diseases that can be treated with cellular transplantation

  **Disease/disorder**     **Type of cells required for transplantation**
  ------------------------ ------------------------------------------------
  Alzheimer's disease      Nerve cells
  Diabetes                 Islet cells
  Cardiovascular disease   Cardiomyocytes
  Liver disease            Hepatocytes
  Multiple sclerosis       Glial cells
  Osteoarthritis           Chrondrocytes
  Spinal cord injuries     Nerve cells

###### 

Efficiencies of obtaining live offspring or establishing nt-ESC lines between species across a range of donor cells

  **Donor somatic cell**   **Mice**                       **Pigs**                       **Cattle**                                                             **Monkeys**                   **Humans**                                                                                                                                                                                                                                                        
  ------------------------ ------------------------------ ------------------------------ ---------------------------------------------------------------------- ----------------------------- ------------------------------------------------- ------------------------------------------------ --------------------------------------------------------------------- ------------------------------- --------------------------- ---------------------------- -------------------------------------------------
  Blastomere               13%--26% ([@b42-sccaa-1-11])                                  2.1% (RS [@b84-sccaa-1-11])                                                                                                                                                                                                                                                   7% ([@b64-sccaa-1-11])                                                                   
  Carcinoma                                               50% ([@b11-sccaa-1-11])                                                                                                                                                                                                                                                                                                                                                                               
  Cumulus/granulosa        1%--3% ([@b99-sccaa-1-11])     9%--19% ([@b99-sccaa-1-11])    0.6%--7% ([@b54-sccaa-1-11]; [@b80-sccaa-1-11])                                                      1%--23% ([@b34-sccaa-1-11]; [@b110-sccaa-1-11])   13% ([@b101-sccaa-1-11])                         16% ([@b69-sccaa-1-11])                                                                                                           4%--9% ([@b41-sccaa-1-11])   
  Embryonic stem cells     11%--21% ([@b83-sccaa-1-11])   50% ([@b11-sccaa-1-11])                                                                                                             31%--70% ([@b19-sccaa-1-11])                      59% ([@b19-sccaa-1-11])                          34% ([@b67-sccaa-1-11])                                                                                                                                        
  Fibroblasts              1% ([@b99-sccaa-1-11])         13%--33% ([@b99-sccaa-1-11])   0.2%--8.7% ([@b16-sccaa-1-11]; [@b100-sccaa-1-11]; [@b6-sccaa-1-11])   1%--38% ([@b76-sccaa-1-11])   3%--29% ([@b102-sccaa-1-11])                      60%--80% ([@b111-sccaa-1-11])                                                                                                                          5.7% ([@b12-sccaa-1-11])    23% ([@b29-sccaa-1-11])      
  Neural stem cells                                       64% ([@b10-sccaa-1-11])                                                                                                                                                                                                                                                                                                                                                                               
  Sertoli                  6% ([@b99-sccaa-1-11])         27% ([@b99-sccaa-1-11])                                                                                                                                                                                                                                                                                                                                                                               
  Parthenogenesis                                         2.3% ([@b87-sccaa-1-11])                                                                                                            14.3% ([@b108-sccaa-1-11])                                                                         25%--58% ([@b68-sccaa-1-11])                                                                                                                                   26%--66% ([@b82-sccaa-1-11]; [@b61-sccaa-1-11])
  Fertilization/ISCI       60%--80% ([@b99-sccaa-1-11])   25%--68% ([@b99-sccaa-1-11])   50% ([@b112-sccaa-1-11])                                               17% ([@b57-sccaa-1-11])       40%--60% ([@b111-sccaa-1-11])                     2%--8% ([@b101-sccaa-1-11]; [@b39-sccaa-1-11])   38%--50% ([@b69-sccaa-1-11]; [@b115-sccaa-1-11]; [@b12-sccaa-1-11])   89%--95% ([@b105-sccaa-1-11])   12.5% ([@b90-sccaa-1-11])                                27--36% ([@b96-sccaa-1-11]; [@b15-sccaa-1-11])

Percentage of transferred blastocysts to a surrogate mother.

Percentage of blastocysts giving rise to nt-ESC lines.

Percentage of cleaved embryos developing to morulae/blastocyst stages.

**Abbreviations:** ESC, embryonic stem cell; ISCI, intracytoplasmic sperm injection.
